Review on lymphomatoid papulosis (LyP) with 6p25.3 rearrangement, with data on clinics, and the genes implicated.
Clinics
The lesions are usually restricted to a single body area. Affected sites included the head and neck, upper torso, and extremities. Lesions ranged in size from 0.3 cm to 1.0 cm in diameter and had variable scale but no ulceration. No patient had disseminated cutaneous disease or clinical evidence of extracutaneous disease.
Pathology
The histological features are remarkably consistent and different from the other types of cutaneous LyPs. Salient features include: prominent dermal nodule with the overlying epidermis showing pagetoid reticulosis-like histological changes. Marked periadnexal involvement is sometimes present. Tumor cells are mostly small to mediumsized with markedly irregular nuclei. Lesions show high mitotic rate and the presence of frequent apoptotic bodies. Necrosis is absent. No significant amount of eosinophils and neutrophils are present.
Treatment
No established treatment. Most of the lesions involute spontaneously and without therapy. Consideration to radiation, injection with kenalog or excision can be made depending on individual presentation.
Evolution
Similar to other types of LyP, recurring-remitting course.
Prognosis
According to the series of 11 patients the prognosis is good (Karai et al., 2013) . 
Cytogenetics

Cytogenetics morphological
Karyotypic findings have not been reported.
Probes
See Karai et al., 2013. 
Additional anomalies
Unknown.
Variants
Genes involved and proteins
Note
The breakapart probe used to identify 6p25.3 rearrangements in LyP spans both the DUSP22 and the IRF4 genes. The specific breakpoints have not been reported in LyP. In ALK-negative anaplastic large cell lymphomas (ALCLs), 6p25.3 breakpoints in or near either gene have been reported (Feldman et al., 2011) . The partner locus was confirmed to be 7q32.3 in a single case of LyP tested, analogous to the t(6;7)(p25.3;q32.3) reported in ALCLs, but was not investigated in the remaining reported cases.
DUSP22
Location 6p25.3 Protein DUSP22 encodes a dual-specificity phosphatase that inhibits T-cell antigen-receptor signaling in T cells by inactivating the MAP kinase, ERK2. The expression and function of DUSP22 in cases of LyP with 6p25.3 rearrangements have not been reported.
IRF4
Location 6p25.3 Protein IRF4 encodes a transcription factor, IRF4/MUM1, critical in lymphocyte activation and differentiation. Although IRF4/MUM1 is expressed in most cases of LyP, the expression and function of IRF4/MUM1 in cases of LyP with 6p25.3 rearrangements have not been reported.
